Business briefs: Celgene

Share this article:

Celgene's Pomalyst (pomalidomide), an oral treatment for relapsed and refractory multiple myeloma, was approved by the FDA this week. It is the second such treatment approved for the blood cancer in the past seven months with Onyx's Kyprolis (carfilzomib) approved last July. Approval was based on response rate while clinical benefit (i.e. survival, symptoms) has not been verified by regulators. The treatment will only be available to patients through a restricted distribution program, Pomalyst REMS. Analysts forecast Pomalyst sales to reach $1.1 billion in 2017.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M inVISION